I was recently interviewed by Business Insider about the FDA’s review of a potential new anti-epilepsy drug, Epidiolex. In Phase III clinical trials, 44% of patients with Lennox-Gastaut Syndrome (LGS) and 43% of patients with Dravet syndrome who used Epidiolex saw a 50% or greater reduction in their seizures compared to 24% and 27% of participants who took the placebo.
Epidiolex could be the first drug derived from cannabidiol (CBD) to gain FDA approval. Unlike THC, one of the other components in marijuana, cannabidiol is not an intoxicant. So, Epidiolex does not have hallucinogenic effects. The FDA is expected to make its final decision about Epidiolex in June.
In other news: CURE is announcing the expansion of its Day of Science event; CURE is urging insurance companies to maintain reasonable access to Sabril; and you can now support CURE while drinking your morning cup of coffee. Read on….
DAY OF SCIENCE IS EXPANDING TO SIX LOCATIONS!
CURE’s 2018 Day of Science events kick-off in June. At these free events, you can learn about cutting-edge epilepsy therapies and treatments, via:
- Q&A sessions with panels of epilepsy physicians
- Small-group roundtable discussions led by experts
You’ll also get the opportunity to engage with others in the epilepsy community.
Registration is now open for the Days of Science in:
Stay tuned for details about CURE’s Days of Science in the following cities:
- Los Angeles
Interested in volunteering? Please contact the Day of Science team at DOS@CUREepilepsy.org or (312) 255-1801.